Casdin Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $26.6M | Sell |
|
|||||
|
2025
Q1 | $32.4M | Sell |
|
|||||
|
2024
Q4 | $32.9M | Sell |
|
|||||
|
2024
Q3 | $46.8M | Hold |
|
|||||
|
2024
Q2 | $41.3M | Sell |
|
|||||
|
2024
Q1 | $53.5M | Buy |
|
|||||
|
2023
Q4 | $37.3M | Sell |
|
|||||
|
2023
Q3 | $35.4M | Sell |
|
|||||
|
2023
Q2 | $53.2M | Buy |
|
|||||
|
2023
Q1 | $54.1M | Sell |
|
|||||
|
2022
Q4 | $86.7M | Sell |
|
|||||
|
2022
Q3 | $130M | Sell |
|
|||||
|
2022
Q2 | $117M | Sell |
|
|||||
|
2022
Q1 | $163M | Hold |
|
|||||
|
2021
Q4 | $170M | Hold |
|
|||||
|
2021
Q3 | $189M | Hold |
|
|||||
|
2021
Q2 | $170M | Buy |
|
|||||
|
2021
Q1 | $124M | Buy |
|
|||||
|
2020
Q4 | $101M | Buy |
|
|||||
|
2020
Q3 | $90.3M | Buy |
|
|||||
|
2020
Q2 | $81.5M | Sell |
|
|||||
|
2020
Q1 | $63.7M | Buy |
|
|||||
|
2019
Q4 | $59.3M | Sell |
|
|||||
|
2019
Q3 | $48.3M | Sell |
|
|||||
|
2019
Q2 | $47.2M | Buy |
|
|||||
|
2019
Q1 | $41.6M | Buy |
|
|||||
|
2018
Q4 | $25.9M | Buy |
|
|||||
|
2018
Q3 | $23.6M | Hold |
|
|||||
|
2018
Q2 | $26.6M | Buy |
|
|||||
|
2018
Q1 | $29.8M | Buy |
|
|||||
|
2017
Q4 | $25.4M | Hold |
|
|||||
|
2017
Q3 | $23.5M | Buy |
|
|||||
|
2017
Q2 | $8.38M | Buy |
|
|||||
|
2017
Q1 | $2.82M | Sell |
|
|||||
|
2016
Q4 | $3.18M | Buy |
|
|||||
|
2016
Q3 | $2.64M | Sell |
|
|||||
|
2016
Q2 | $4.02M | Sell |
|
|||||
|
2016
Q1 | $5.65M | Buy |
|
|||||
|
2015
Q4 | $5.65M | Buy |
|